Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-03-04
2008-03-04
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
Reexamination Certificate
active
07338656
ABSTRACT:
A method for decreasing the body fat proportion, increasing lean body mass, increasing bone density, or improving the rate of bone healing, or all, of a subject. Embodiments of the invention include delivering a heterologous nucleic acid sequence encoding GHRH or functional biological equivalent thereof into the cells of the subject and allowing expression of the encoded gene to occur while the modified cells are within the subject.
REFERENCES:
patent: 4223019 (1980-09-01), Momany
patent: 4223020 (1980-09-01), Momany
patent: 4223021 (1980-09-01), Momany
patent: 4224316 (1980-09-01), Momany
patent: 4226857 (1980-10-01), Momany
patent: 4228156 (1980-10-01), Momany
patent: 4228158 (1980-10-01), Momany
patent: 4410512 (1983-10-01), Bowers
patent: 4684611 (1987-08-01), Schilperoort
patent: 4833166 (1989-05-01), Grosvenor
patent: 4839344 (1989-06-01), Bowers
patent: 4952500 (1990-08-01), Finnerty
patent: 4956288 (1990-09-01), Barsoum
patent: 5023322 (1991-06-01), Kovacs
patent: 5036045 (1991-07-01), Thorner
patent: RE33699 (1991-09-01), Drengler
patent: 5061690 (1991-10-01), Kann
patent: 5084442 (1992-01-01), Felix
patent: 5134120 (1992-07-01), Boyd
patent: 5137872 (1992-08-01), Seely
patent: 5292721 (1994-03-01), Boyd
patent: 5302523 (1994-04-01), Coffee
patent: 5322783 (1994-06-01), Tomes
patent: 5384253 (1995-01-01), Krzyzek
patent: 5439440 (1995-08-01), Hofmann
patent: 5464765 (1995-11-01), Coffee
patent: 5486505 (1996-01-01), Bowers
patent: 5538877 (1996-07-01), Lundquist
patent: 5538880 (1996-07-01), Lundquist
patent: 5550318 (1996-08-01), Adams
patent: 5563055 (1996-10-01), Townsend
patent: 5580859 (1996-12-01), Felgner
patent: 5589466 (1996-12-01), Felgner
patent: 5591616 (1997-01-01), Hiei
patent: 5610042 (1997-03-01), Chang
patent: 5656610 (1997-08-01), Shuler
patent: 5696089 (1997-12-01), Felix
patent: 5702384 (1997-12-01), Umeyama
patent: 5702932 (1997-12-01), Hoy
patent: 5704908 (1998-01-01), Hofmann
patent: 5736524 (1998-04-01), Content
patent: 5756264 (1998-05-01), Schwartz
patent: 5776901 (1998-07-01), Bowers
patent: 5780448 (1998-07-01), Davis
patent: 5789215 (1998-08-01), Berns
patent: 5792747 (1998-08-01), Schally
patent: 5846936 (1998-12-01), Felix
patent: 5847066 (1998-12-01), Coy
patent: 5874534 (1999-02-01), Vegeto
patent: 5935934 (1999-08-01), Vegeto
patent: 5945100 (1999-08-01), Fick
patent: 5981274 (1999-11-01), Tyrrell
patent: 5994624 (1999-11-01), Trolinder
patent: 6165755 (2000-12-01), Sherwood et al.
patent: 6423693 (2002-07-01), Schwartz et al.
patent: 6486134 (2002-11-01), Lee et al.
patent: 6759393 (2004-07-01), Morsey et al.
patent: 2004/0192593 (2004-09-01), Draghia-Akli et al.
patent: WO 94/09699 (1994-05-01), None
patent: WO- 95/06128 (1995-03-01), None
patent: WO 99/05300 (1999-02-01), None
patent: WO 01/06988 (2001-02-01), None
patent: WO 01/06988 (2001-02-01), None
patent: WO 01/21801 (2001-03-01), None
patent: WO 01/66149 (2001-09-01), None
patent: WO 02/061037 (2002-08-01), None
patent: WO 04/018697 (2004-03-01), None
Anderson et al., Nature, vol. 392, pp. 25-30, 1998.
Verma, Nature, vol. 389, pp. 239-242, 1997.
Romano et al. Stem Cells, 18:19-39, 2000.
Fenske et al., 2001, Current Opnion in Molecular Therapeutics, 3: 153-158.
Abruzzese, R. V., D. Godin, M. Burcin, V. Mehta, M. French, Y. Li, B. W. O'Malley, and J. L. Nordstrom. 1999. Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum. Gene Ther. 10:1499-1507.
Abruzzese, R. V., D. Godin, V. Mehta, J. L. Perrard, M. French, W. Nelson, G. Howell, M. Coleman, B. W. O'Malley, and J. L. Nordstrom. 2000. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol. Ther. 2:276-287.
Aihara, H. and J. Miyazaki. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:867-870.
Almendro, N., T. Bellon, C. Rius, P. Lastres, C. Langa, A. Corbi, and C. Bernabeu. 1996. Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J. Immunol. 157:5411-5421.
Aratani, Y., R. Okazaki, and H. Koyama. 1992. End extension repair of introduced targeting vectors mediated by homologous recombination in mammalian cells. Nucleic Acids Res. 20:4795-4801.
Argente, J., J. Pozo, and J. A. Chowen. 1996. The growth hormone axis: control and effects. Hormone Research 45 Suppl 1:9-11.
Barr, E. and J. M. Leiden. 1991. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254:1507-1509.
Bercu, B. B., R. F. Walker 1997. Growth Hormone Secretagogues In Children With Altered Growth. Acta Paediatrica 86:102-106.
Bergsma, D. J., J. M. Grichnik, L. M. Gossett, and R. J. Schwartz. 1986. Delimitation and characterization of cis-acting DNA sequences required for the regulated expression and transcriptional control of the chicken skeletal alpha-actin gene. Molecular & Cellular Biology 6:2462-2475.
Bettan, M., F. Emmanuel, R. Darteil, J. M. Caillaud, F. Soubrier, P. Delaere, D. Branelec, A. Mahfoudi, N. Duverger, and D. Scherman. 2000. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol. Ther. 2:204-210.
Blethen, S. L. and A. C. Rundle. 1996. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm. Res. 46:113-116.
Boshart, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstein, and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521-530.
Bureau, M. F., J. Gehl, V. Deleuze, L. M. Mir, and D. Scherman. 2000. Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim. Biophys. Acta 1474:353-359.
Carbonelli, D. L., E. Corley, M. Seigelchifer, and J. Zorzopulos. 1999. A plasmid vector for isolation of strong promoters inEscherichia coli. FEMS Microbiol. Lett. 177:75-82.
Chandler, S. D., A. Mayeda, J. M. Yeakley, A. R. Krainer, and X. D. Fu. 1997. RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins. Proc. Natl. Acad. Sci. U. S. A. 94:3596-3601.
Chen, C. and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 7:2745-2752.
Chevalier, R. L., S. Goyal, A. Kim, A. Y. Chang, D. Landau, and D. Leroith. 2000. Renal tubulointerstitial injury from ureteral obstruction in the neonatal rat is attenuated by IGF-1. Kidney Int. 57:882-890.
Cocea, L. 1997. Duplication of a region in the multiple cloning site of a plasmid vector to enhance cloning-mediated addition of restriction sites to a DNA fragment. Biotechniques 23:814-816.
Cohn, S. H., A. N. Vaswani, S. Yasumura, K. Yuen, and K. J. Ellis. 1984. Improved models for determination of body fat by in vivo neutron activation. Am. J Clin. Nutr. 40:255-259.
Corpas, E., S. M. Harman, M. A. Pineyro, R. Roberson, and M. R. Blackman. 1993. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism 76:134-138.
Dai, B., H. Wu, E. Holthuizen, and P. Singh. 2001. Identification of a novel cis element required for cell density-dependent down-regulation of insulin-like growth factor-2 P3 promoter activity in Caco2 cells. J. Biol. Chem. 276:6937-6944.
Danko, I. and J. A. Wolff. 1994. Direct gene transfer into muscle. [Review]. Vaccine 12:1499-1502.
Darquet, A. M., B. Cameron, P. Wils, D. Scherman, and J. Crouzet. 1997. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 4:1341-1349.
Darquet, A. M., R. Rangara, P. Kreiss, B. Schwartz, S. Naimi, P. Delaere, J. Crouzet, and D. Scherman. 1999. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. 6:209-218.
Davis, H. L., R. G. Whalen, and B. A. Demeneix. 1993. Direct gene transfer into skeletal muscle in vi
Draghia-Akli Ruxandra
Schwartz Robert J.
Baylor College of Medicine
Pepper Hamilton LLP
Whiteman Brian
LandOfFree
Composition and method to alter lean body mass and bone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method to alter lean body mass and bone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method to alter lean body mass and bone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2803448